Indeed, BPC 157 has a particular potential to act as combining therapy in the whole gastrointestinal tract (5, 6) (esophageal (41-43), gastric (31, 36, 44), duodenal (29-33) and colitis lesions counteraction (12)), and the ameliorated course after the experimental creation of the more complex conditions and complications (44-46) in rats, including those induced by various NSAIDs (47-49)
GHK is a high-affinity copper-binding peptide that has been proposed to function as a physiological copper carrier and delivery agent moving copper between proteins and binding sites in plasma and in tissues, with downstream consequences for processes that depend on copper availability and on GHK-dependent signaling
What is in the GLOW peptide blend / stack
There is no conclusive long-term human data, so it's recommended to use BPC-157 under the guidance of a healthcare provider
In those cases, BPC-157 may support surrounding soft tissue in some patients, but it should not be framed as a treatment that reverses the underlying structural problem
